Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ALS: first human trial of Gene-Targeting drug begins

NCT ID NCT06351592

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called ALN-SOD in people with ALS caused by a mutation in the SOD1 gene. The drug is given via spinal injection to target the root cause of the disease. The main goal is to check safety, but researchers will also measure effects on biomarkers and symptoms. 54 participants are being recruited for this early-stage trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ALN-SOD

What this could lead to

If it works, this could slow or stop the progression of ALS in people with SOD1 mutations, potentially preserving function and extending life.

What could go wrong

This is a very early (first-in-human) trial with only 54 participants, so safety and effectiveness are not yet known. The drug may not work or could cause unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis amyotrophic lateral sclerosis type 1 familial amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS (ALS) MUTATION IN THE SUPEROXIDE DISMUTASE-1 (SOD1) GENE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Concord Repatriation General Hospital

    RECRUITING

    Concord, New South Wales, 2139, Australia

  • Hanyang University Seoul Hospital

    RECRUITING

    Seoul, 04763, South Korea

  • Hokkaido University Hospital

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • KU Leuven

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Kaohsiung Chang Gung Memorial Hospital

    RECRUITING

    Kaohsiung City, 83301, Taiwan

  • Kyoto University Hospital

    RECRUITING

    Kyoto, 606-8507, Japan

  • Macquarie University

    RECRUITING

    Sydney, New South Wales, 2109, Australia

  • Montreal Neurological Institute and Hospital

    RECRUITING

    Montreal, Quebec, H3A 2B4, Canada

  • Noorlands University Hospital-Department of Neurology

    RECRUITING

    Umeå, Noorland, 907 37, Sweden

  • Seoul National University Hospital

    RECRUITING

    Seoul, 3080, South Korea

  • Sunnybrook Research Institute

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Sunshine Coast University Hospital

    RECRUITING

    Birtinya, Queensland, 4575, Australia

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11211, Taiwan

  • Toho University Omori Medical Center

    RECRUITING

    Ōta-ku, Tokyo, 143-8541, Japan

  • Tokushima University Hospital

    RECRUITING

    Tokushima, Tokushima, 770-0042, Japan

  • University Hospital - London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5A5, Canada

  • University of Alberta Hospital, Edmonton, Division of Neurology

    RECRUITING

    Edmonton, Alberta, T6G 2G3, Canada